» Articles » PMID: 19684060

Etiology, Baseline Characteristics, and Biochemical Diagnosis of GH Deficiency in the Adult: Are There Regional Variations?

Overview
Specialty Endocrinology
Date 2009 Aug 18
PMID 19684060
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Previous work has examined potential links between the etiology of GH deficiency (GHD) and the baseline characteristics of the patients including biochemical and psychometric parameters. Using an update of the KIMS pharmaco-epidemiological database (Pfizer International Metabolic Database), we addressed the question how well such results can be generalized and whether regional differences may play a role. From 30 different countries, 13 167 GH-deficient patients were included in KIMS at the data close in December 2008. In order to explore country-specific differences of baseline characteristics documented in KIMS, separate analyses of baseline characteristics of adult-onset GHD patients (n=7708) were performed for the six largest contributing European countries and the United States. This analysis revealed striking regional variations in the pathogenesis of the disease, clinical characteristics such as body mass index, and in the classical features of the metabolic syndrome such as blood pressure or lipid status between countries. Moreover, the approach to endocrine function testing was widely different between countries, as well as the distribution of etiologies of GHD. These data suggest that a complex relation between biochemical and clinical signs of GHD exists, and that the spectrum of adult GHD syndrome is influenced by regional diagnostic and clinical particularities.

Citing Articles

Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in Belgium.

Staels W, De Schepper J, Becker M, Lysy P, Klink D, Logghe K Front Endocrinol (Lausanne). 2024; 15:1459998.

PMID: 39415786 PMC: 11482521. DOI: 10.3389/fendo.2024.1459998.


Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis.

Yuen K, Johannsson G, Ho K, Miller B, Bergada I, Rogol A Endocr Connect. 2023; 12(7).

PMID: 37052176 PMC: 10305501. DOI: 10.1530/EC-22-0504.


Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients.

Johannsson G, Touraine P, Feldt-Rasmussen U, Pico A, Vila G, Mattsson A J Clin Endocrinol Metab. 2022; 107(7):1906-1919.

PMID: 35368070 PMC: 9202689. DOI: 10.1210/clinem/dgac199.


Somatropin therapy in italian adults with growth hormone deficiency.

Pricci F, Rotondi D, Villa M, Valerio A, Agazio E, Roazzi P BMC Endocr Disord. 2022; 22(1):52.

PMID: 35241041 PMC: 8895664. DOI: 10.1186/s12902-022-00960-5.


Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Ratku B, Sebestyen V, Erdei A, Nagy E, Szabo Z, Somodi S Pituitary. 2022; 25(2):211-228.

PMID: 35106704 PMC: 8894188. DOI: 10.1007/s11102-022-01207-1.